Previous 10 | Next 10 |
DUBLIN , Nov. 29, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of t...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
AbbVie ( ABBV ) has seen a sharp rally in the stock following the large dip over the Summer, after announcing the debt-fueled deal to acquire Allergan ( AGN ). At the current price of $87, the stock still yields an incredible 5.4% for yield-starved investors. The key to AbbVie is not payin...
AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT) were born of the same parent but separated at birth. In 2013, Abbott Laboratories split into two companies, one primarily a medical device maker (which retained the parent's name) and the other a pharmaceutical company. That's where...
This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Dan Loeb’s Third Point Portfoli...
The manufacturer’s textured products are linked to large cell lymphoma Allergan, the manufacturers of BIOCELL textured “gummy” breast implants, is the target of a second proposed national class-action lawsuit by consumer-rights law firm FeganScott. The expanded com...
Markets are bipolar in their sentiment on AbbVie ( ABBV ). When it first announced the buyout of Allergan ( AGN ) in June, the stock began a four-month-long descent. By September, sentiment changed. Drug stocks staged a broad rally, taking AbbVie stock with it. Strong Q4 results, a dividend ...
The MannKind ( MNKD ) saga continues to unfold as it travels a desolate highway to a future that is becoming bleaker for those opting to own their common stock. Within the next two months, we will have seen Afrezza being FDA approved during seven (7) calendar years. As for being actively marke...
As my readers know, we plan to retire at age 54 in July 2020 and roam the country in our motorhome for a few years before settling into one location. Our plan consists of different time periods, each with a different investment purpose. They are: From age 54 to 59.5, we will not yet be abl...
Merger activity decreased, with three new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Carolina Financial Corporation (CARO) by United Bankshares (UBSI) for $1.1 billion in an all-stock deal. Under the terms of the agreement, United will...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...
2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...
2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...